Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.58 |
| ▸ | EHMT1 | Q9H9B1 | 8/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6096022 | 0.99 | EHMT2 (0.57) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| SCHEMBL6098975 | 0.90 | EGFR (0.58) | EGFRABL1BCRSRCKIT | |
| Hydrochloric Acid SCHEMBL6097118 | 0.89 | EGFR (0.57) | EGFRABL1BCRSRCKIT | |
| SCHEMBL29636829 | 0.83 | EHMT2 (0.76) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| SCHEMBL18986541 | 0.83 | EHMT2 (0.65) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| SCHEMBL8526894 | 0.83 | EHMT2 (0.76) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| SCHEMBL17372646 | 0.82 | EHMT2 (0.64) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| Hydrochloric Acid SCHEMBL6433786 | 0.82 | EHMT2 (0.74) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| SCHEMBL2748129 | 0.82 | EHMT2 (0.74) | EHMT2EHMT1DNMT1SPIN1EGFR | |
| SCHEMBL6096985 | 0.80 | KDR (0.60) | EGFRSRCFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309587-B1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-6887874-B2 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030212055-A1 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212055-A1 | Cinnoline compounds | VEGFA, PGF, CCR7 | EHMT2 3136/4885EHMT1 2064/4885DNMT1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.